Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Adenocarcinoma of the Prostate Histologically confirmed adenocarcinoma of the prostate, which is localized to the prostate ( within 24 months of screening) 2. Absence of lymph node, bone or other metastases as determined by MRI and CT scan, Bone Scan or nano-MRI (≤3 months prior to first administration) 3. Men between 18 and 75 years inclusive 4. ECOG status 0 or 1 5. Ability to understand and willingness to sign informed consent 6. Adequate liver, renal and bone marrow function: AST & ALT < 2.5 x ULN, total bilirubin < 1.5 x ULN, Alkaline phosphatase < 3 x ULN, Serum creatinine < 1.5 x ULN, Haemoglobin > 9.0 g/dL (5.59 mmol/L), Platelet count > 100x10*9/L, Neutrophils > 1.5x10*9/L, INR < 1.5xULN 7. eGFR ≥ 30 mL/min, using the Cockcroft Gault Equation: Creatinine Clearance = [{(140 age in years) x (weight in kg)} x 1.23] /serum Creatinine in Mmol/L  Tumor not accessible for injection 2. Prior treatment of prostate cancer with radiation therapy or brachytherapy 3. Prior use of chemotherapy/hormone therapy for treatment of cancer 4. Target tumor adherent to a major vascular structure 5. Participation in any investigational drug study within the last 12 months prior to first administration of ORCA-010 6. Clinically significant active infection (viral or bacterial) 7. Known immunosuppressive diseases (e.g. HIV, Hepatitis B and C) 8. History of any other oncological malignancy, excluding basal cell carcinoma of the skin, in the past 5 years 9. Not willing to refrain from sexual activities or use a double barrier contraceptive device (condom with foam or vaginal suppository, diaphragm with spermicide) after administration of ORCA-010 and until 42 days after the last ORCA-010 administration 10. Severe obesity defined as Body Mass Index (BMI) > 30 kg/m2 11. Positive for adenovirus in throat swap or serum as determined by PCR at screening 12. Recent (within 3 months prior to enrolment in the study) history of alcohol abuse or other substances such as barbiturates, cannabinoids and amphetamines or a positive urine screen for drugs of abuse 13. Use of medication known to have immunosuppressive effects, except topical/inhaled steroids under 10 mg/day prednisolone equivalent (See Appendix 7) 14. Use of systemic antiviral medication within 3 months prior to enrolment in the study 15. Use of any anti-coagulants/blood thinner except for ASA 81mg 16. Any condition that in the opinion of the Investigator could interfere with the conduct of the study 17. For Part B only: Subjects enrolled in Part A of the study